Researchers from the Respiratory Infections and Immunocompromised Host group at IDIBELL and the Bellvitge University Hospital have shown that monotherapy with a 3rd generation cephalosporin is effective and safe as a treatment for this serious infectious disease. These results will change international recommendations for its management.
Monotherapy could replace combination therapy in endocarditis Read More »
Thanks to the model, the IDIBELL team detected that one of the siblings had an additional genetic variant responsible for the greater severity of the pathology. These models offer the possibility of exploring each patient’s pathology and designing an individualized approach.
Accreditation was first obtained in 2021 and requires an annual review to verify that the necessary requirements are maintained.
The Clinical Research and Clinical Trials Unit obtains the ISO 9001:2015 recertification Read More »
The European EprObes project, which uses a methodology based on Artificial Intelligence, will study how to prevent obesity through early identification of biomarkers, risk factors, prognosis and intervention.
IDIBELL participates in a €10M European project to prevent childhood obesity Read More »
The project, promoted by IDIBELL and CNIO, together with seven other research institutes, will combine artificial intelligence with cutting-edge molecular biology techniques to provide predictive medicine tools to the National Health Service.
3.2 million euros to identify new genetic variants responsible for hereditary cancers Read More »
The journal New England Journal of Medicine has published the results of the NADIM II study, which confirms the great benefit of chemo-immunotherapy with nivolumab before surgery on locally advanced tumors and is consolidated worldwide as the standard of treatment.
This is a relevant position, endorsed by the scientific and care trajectory of Dr. Maria Molina, head of the Pneumology research group of the Institute of Bellvitge Biomedical Research.
The results of the study led by IDIBELL and the Hospital de Bellvitge solve a pending issue and open new ways to improve the patients’ life quality with safe and effective treatment.
The coordinator of the IDIBELL Systemic, Vascular and Aging Diseases group will be globally responsible, together with two other editors, for the section on Rare Cardiovascular Diseases of the Orphanet Journal of Rare Diseases.
Funded by the European Union, the project aims to develop, evaluate and disseminate a methodological implementation framework for cancer known as the ‘Integrated Implementation Kit’ in six risk factors, such as tobacco, alcohol, ‘sun exposure, the human papilloma virus, nutrition and physical activity.
